Directorio de personas
Manuel Portero Otin

Manuel Portero Otin

Grado: Doctor/a

973 702 408
manuel.portero(ELIMINAR)@udl.cat

ResearcherID: http://www.researcherid.com/rid/B-7122-2009

Grupos

Publicaciones

  • Morato, L; Ruiz, M; Boada, J; Calingasan, NY; Galino, J; Guilera, C; Jove, M; Naudi, A; Ferrer, I; Pamplona, R; Portero-Otin, M; Serrano, M; Beal, FM; Fourcade, S; Pujol, A

    Integrative -omics analyses uncovers inflammatory lipid cascades in adrenoleukodystrophy

    Glia 63 24-24. .

  • Serrano, JCE; Jove, M; Gonzalo, H; Pamplona, R; Portero-Otin, M

    Nutridynamics: mechanism(s) of action of bioactive compounds and their effects

    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION 66 22-30. .

    [doi:10.3109/09637486.2015.1035231]

  • Uribarri J; Del Castillo MD; de la Maza MP; Filip R; Gugliucci A; Luevano-Contreras C; Macías-Cervantes MH; Markowicz Bastos DH; Medrano A; Menini T; Portero-Otin M; Rojas A; Sampaio GR; Wrobel K; Wrobel K; Garay-Sevilla ME

    Dietary Advanced Glycation End Products and Their Role in Health and Disease

    Advances in Nutrition 6 461-473. .

    [doi:10.3945/an.115.008433]

  • Naudí A; Cabré R; Jové M; Ayala V; Gonzalo H; Portero-Otín M; Ferrer I; Pamplona R

    Lipidomics of Human Brain Aging and Alzheimer's Disease Pathology

    International Review of Neurobiology 122 133-189. .

    [doi:10.1016/bs.irn.2015.05.008]

  • Ost M; Keipert S; van Schothorst EM; Donner V; van der Stelt I; Kipp AP; Petzke KJ; Jove M; Pamplona R; Portero-Otin M; Keijer J; Klaus S

    Muscle mitohormesis promotes cellular survival via serine/glycine pathway flux

    FASEB JOURNAL 29 1314-1328. .

    [doi:10.1096/fj.14-261503]

  • López-González I; Schlüter A; Aso E; Garcia-Esparcia P; Ansoleaga B; LLorens F; Carmona M; Moreno J; Fuso A; Portero-Otin M; Pamplona R; Pujol A; Ferrer I

    Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice: Correlations With Plaques, Tangles, and Oligomeric Species

    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 74 319-344. .

    [doi:10.1097/NEN.0000000000000176]

  • Purroy, F; Jove, M; Portero, M; Cambray, S; Suarez, I; Sanahuja, J; Farre, J; Benabdelhak, I

    Metabolomics discriminate etiologic subtypes among TIA patients

    INTERNATIONAL JOURNAL OF STROKE 10 222-222. .

  • Jové M; Mauri-Capdevila G; Suárez I; Cambray S; Sanahuja J; Quílez A; Farré J; Benabdelhak I; Pamplona R; Portero-Otín M; Purroy F

    Metabolomics predicts stroke recurrence after transient ischemic attack

    Neurology 84 36-45. .

    [doi:10.1212/WNL.0000000000001093]

  • Ansoleaga B; Jové M; Schlüter A; Garcia-Esparcia P; Moreno J; Pujol A; Pamplona R; Portero-Otín M; Ferrer I

    Deregulation of purine metabolism in Alzheimer's disease

    NEUROBIOLOGY OF AGING 36 68-80. .

    [doi:10.1016/j.neurobiolaging.2014.08.004]

  • Cacabelos, D.; Ayala, V.; Ramírez-Nunez, O.; Granado-Serrano, A.B.; Boada, J.; Serrano, J.C.E.; Cabré, R.; Nadal-Rey, G.; Bellmunt, M.J.; Ferrer, I.; Pamplona, R.; Portero-Otin, M.

    Dietary Lipid Unsaturation Influences Survival and Oxidative Modifications of an Amyotrophic Lateral Sclerosis Model in a Gender-Specific Manner

    NEUROMOLECULAR MEDICINE 16 669-685. .

    [doi:10.1007/s12017-014-8317-7]

  • Jové M; Naudí A; Portero-Otin M; Cabré R; Rovira-Llopis S; Bañuls C; Rocha M; Hernández-Mijares A; Victor VM; Pamplona R

    Plasma lipidomics discloses metabolic syndrome with a specific HDL phenotype

    FASEB JOURNAL 28 5163-5171. .

    [doi:10.1096/fj.14-253187]

  • Blasco G; Puig J; Daunis-I-Estadella J; Molina X; Xifra G; Fernández-Aranda F; Pedraza S; Ricart W; Portero-Otín M; Fernández-Real JM

    Brain Iron Overload, Insulin Resistance, and Cognitive Performance in Obese Subjects: A Preliminary MRI Case-Control Study

    Diabetes Care 37 3076-3083. .

    [doi:10.2337/dc14-0664]

Proyectos

  • Natural microbicides from rice against current and emerging infectious diseases
  • Humanised mouse models to study ATG4B cryptic exon involvement in ALS pathogenesis and its potential as disease biomarker (Hum4ALS)
  • Targeting cryptic exons as biomarkers and ALS therapy
  • Desregulacion de TDP-43,eje clave en la ELA: Caracterización de firmas lipidómicas, transcriptómicas y autofágicas en muestras específicas de pacientes para biomarcadores y reposicionamiento
  • The role of defects in mitochondria-associated ER membranes (MAM) to Amyotrophic Lateral Sclerosis
  • Perspectivas clínicas de la biología de sistemas aplicada al análisis de placas carotídeas humanas: ILER-CAROTID
  • Metabolismo lipidico intracelular, procesamiento de ARNm y estrés celular en la encrucijada de la fisiopatología de la esclerosis lateral amiotrófica
  • Identification of compounds for inhibition of ACE2 membrane expression
  • Reposicionamiento terapéutico dirigido a inhibición de expresión de ACE2 y de proteolisis de trímero S viral
  • Determinació de components bioactius derivats de la microbiota mitjançant micromostreig
  • Estrés celulares y alteraciones en los lipidomas neuronales, gliales y extracelulares en la fisiopatología de la esclerosis lateral amiotrófica.
  • "Imagenoma de l'Envelliment": Estudi observacional poblacional per definir biomarcadors d'imatge RM corporal integral i òmics que s'associen al procés d'envelliment i a factors de risc biopsicosocial en subjectes adults i que defineixen la seva trajectòria vital cap a un envelliment saludable o bé la fragilitat i discapacitat.